Poster #009
A Phase I Clinical Trial of B7-H3 CART Therapy for Recurrent Glioblastoma
Mentors: Bita Sahaf Ph.D., Reena Thomas M.D., PhD., David Miklos, M.D., PhD.
Glioblastoma is a common malignant tumor that originates in the spinal cord, brain, or central nervous system, and exhibits overexpression of B7-H3 protein. In B7-H3 Chimeric Antigen Receptor (B7-H3 CAR) T-cell therapy, patients’ T-cells are transduced with B7H3 specific CAR-construct, which targets B7-H3 in cancerous cells and triggers cancer cell death. Our lab studied ten patients with recurrent glioblastoma in a phase I clinical trial to assess the safety of this immunotherapy. Using high-dimensional flow cytometry along with single cell RNA sequencing, we studied CART cell expansion and the presence of myeloid cells. We observed an increase of myeloid cells in patients during the first two CART infusion cycles. These findings suggest a potential regulatory role in controlling the response to CART cells in patients after their infusion treatment.